Targeted analysis of ctDNA using an RCC-targeted NGS panel (including BAP1, KDM5C, MET, MTOR, PBRM1, PIK3CA, PTEN, SETD2, TP53, and VHL genes) revealed detectable plasma ctDNA in only 18.6% of the patients (mostly metastatic ccRCC) [82]. Here, BAP1 is linked to renal cell carcinoma.